Achieve Late Phase Success with Precision

Navigate your late phase journey with efficiency and comprehensive solutions

Navigate complex Phase 2b-3 trials with scale and end-to-end solutions that propel your therapy towards market readiness. Precision for Medicine stands at the forefront of late phase clinical trials, offering scalability, full-service execution, and regulatory readiness to ensure your project's success.

Streamlining Success in Late Phase Trials

Strategic planning, patient recruitment, and operational efficiency are pillars of successful late-phase clinical trials. At Precision, we understand these challenges and offer a suite of services designed to optimize your trial’s performance from patient strategies to global operational execution.

Global CRO
Patient Strategies
Regulatory Approval

Precision Execution with Global Reach

Leverage Precision's full-service outsourcing (FSO) or functional service provider (FSP) solutions to execute your late-phase trials with unmatched efficiency. Our global reach and integrated lab capabilities provide a one-stop solution, delivering consistency and quality across all study sites.

Explore Global CRO
Enhancing Trial Efficiency with Patient-Centric Approaches

Discover how Precision emphasizes patient engagement and the capability to conduct decentralized clinical trials (DCTs), reducing patient burden and improving enrollment. Our strategies are tailored to meet the unique needs of late-phase trials, ensuring high participation rates and diverse participant representation.

Explore DCT
Navigating the Path to Market

With strategic regulatory planning and in-depth expertise with FDA and EMA submissions, Precision navigates the complex regulatory landscape, ensuring your study is positioned for approval. Engage our regulatory strategists to streamline your path to market.

Explore Regulatory Affairs

Broadening Horizons in Late Phase Trials

As you approach the pivotal late stages of clinical development, Precision for Medicine stands ready with a comprehensive suite of augmentative services. These services are meticulously designed to not only support trial execution but also ensure seamless transition to commercialization, amplifying the impact of your therapeutic innovations.

Lab Services
Precision Technologies
IVD & CDX Regulatory

Precision Integrated Labs

In the realm of late-phase development, the nuanced role of biomarkers becomes increasingly pivotal. Precision’s specialty and central lab services adeptly handle biomarker analysis, patient stratification, and safety monitoring, delivering the high-quality, actionable data essential for late-phase trials. Dive deeper into how our lab solutions can propel your therapy’s late-stage success.

Explore Precision’s Labs
Harnessing Technology for Insightful Breakthroughs

Embrace the cutting-edge with Precision Technologies, where tools like Apostream, EpiontisID, and QuartzBio’s Biomarker Data Management redefine the scope of trial insights. With Virtual Sample Management and MetaVate, our technologies offer unparalleled depth to your data analysis, propelling your therapy’s journey with evidence-backed precision.

Explore Precision 360 Intelligence
Regulatory Mastery for IVD & CDx

With a century’s worth of combined expertise, Precision for Medicine’s IVD Regulatory Team offers unparalleled guidance for IVDs and Companion Diagnostics. Across continents and regulatory landscapes, we craft strategies that streamline global assay testing and registrations, ensuring your diagnostics meet global standards and accelerate your therapy's market entry.

Explore IVD & CDX

Precision late phase resources

Discover our collection of resources designed to optimize and accelerate your late phase development.

View all resources

Guiding the Way for Novel Therapeutics in Complex Indications
Download Brochure
Translational and Biomarker Sciences: Enabling Breakthroughs
Download Brochure

Expanding your therapy's impact with Precision

Beyond clinical trials, Precision for Medicine extends your reach into health economics, market access, and medical communications to ensure your therapy achieves its fullest potential and commercial success.
Explore

HEOR Strategy & Evidence

Shaping Value with HEOR

Deploy Precision's HEOR expertise early to articulate your therapy's value, preparing for successful market access. We integrate economic and clinical insights to craft compelling narratives for payers and regulators.

Explore
Explore

Market Access Planning

Navigating Market Access Landscapes

Our strategic market access plans position your therapy for optimal reimbursement and adoption. Precision's insights into payer landscapes guide your product through to commercial viability.

Explore
Explore

HCP & Engagement

Medical Communications for Adoption

Utilize our medical communications expertise to foster therapy awareness and adoption. Precision balances clinical benefits with humanistic elements, enhancing therapeutic choice and market penetration.

Explore

I recognize that relations between Sponsors and CRO vendors can be strained and difficult, often a blaming game; this has never been my experience with this group as it truly felt like a partnership.

— Director, Small Biotech
At so many levels, the Precision for Medicine team has been fantastic. I am very grateful for how responsive and how collaborative the whole team is. Very grateful for their help.

— Director, Midsize Biotech
Precision for Medicine stands out for partnership and versatility. Everything has been completed on time, and we are looking forward to applying the lessons we learned here to future analysis endpoints.

— Vice President, Clinical Operations, Midsize Biotech
We have been delighted with the experience level and work product from the entire project team – they feel like an extension of our internal team.

— Director, Midsize Pharma

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

Discover Explore

Global CRO
Services

Award-winning CRO with deep oncology and rare disease expertise

Explore
Discover Explore

Global Laboratory
Services

Exceptional translational and biomarker sciences with global central lab services

Explore

Biospecimens

Discover Biospecimens
Diagnostics & CDx

Discover Diagnostics & CDx
Data Intelligence

Discover Data Intelligence
Commercialization

Discover Commercialization

Navigating late phase with Precision insights

Stay informed with the latest late phase and clinical trial insights from our experts, who share knowledge, trends, and success stories from the forefront of clinical research.

Explore our blog

Clinical Trials - Regulatory

MHRA's International Recognition Procedure: Fast-Track Access to the UK Market

Dec 03, ‘25 | 8 min read

has not third author: true, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1764696930757, hs_published_at=1764696947929, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/John%20McIntyre.png',altText='John McIntyre',fileId=201584594055}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=51739740}, second={hs_id=200435431440, hs_child_table_id=0, hs_updated_at=1763745269993, hs_published_at=1764696947929, avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/AQ_GlobalAccess_AlexGrosvenor-3.jpg',altText='AQ_GlobalAccess_AlexGrosvenor-3',fileId=182031301743}, lastname=Grosvenor, hs_initial_published_at=1763745278294, hs_created_by_user_id=26433386, hs_created_at=1763745229272, hs_is_edited=false, hs_deleted_at=0, name=Alex, job=Alex Grosvenor is a Senior Vice President and Managing Director at Precision AQ.  Based in London, Alex leads the International Pricing & Market Access Strategy team, which he established in September 2015.  Over the past decade, he has built this team into a successful, thriving practice, with a reputation for delivering high-quality work and excellent recommendation for its clients.   Alex brings more than 20 years’ consulting experience in the biopharmaceutical industry, over 15 of these in pricing & market access.He specialises in complex pricing strategies, including cross-indication strategy, launch-sequencing and international price referencing.  He has worked across multiple therapy areas, including oncology, immunology, cardiovascular, orphan indications and cell & gene therapies., slug=alex-grosvenor, hs_updated_by_user_id=51739740}, third={}})

John M.
Alex G.

Discover

Clinical Trials

New Zealand Clinical Trial Landscape: Speed, Quality & Savings Explained

Nov 21, ‘25 | 7 min read

has not third author: true, (SizeLimitingPyMap: {main={hs_id=167906611101, hs_child_table_id=0, hs_updated_at=1762899997332, hs_published_at=1764696947929, description=Helen brings over 30 years of experience in multinational healthcare, biotech, and pharmaceutical industries, including work with Medical Research Institutes and CROs. She specializes in leading clinical research, drug and device development, and fostering innovative research collaborations. Based in Sydney, Australia, Helen has a strong track record of delivering clinical trials across the APAC region., avatar=Image{width=600,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Helene-Ormandy.png',altText='Helene-Ormandy',fileId=168387434767}, lastname=Ormandy, PhD, hs_initial_published_at=1716212950394, hs_created_by_user_id=2737751, hs_created_at=1716212897654, hs_is_edited=false, hs_deleted_at=0, name=Helen, job=Executive Director, Clinical Operations, slug=helen-ormandy, hs_updated_by_user_id=51739740}, second={hs_id=197935898186, hs_child_table_id=0, hs_updated_at=1761062728726, hs_published_at=1764696947929, description=Hardik Badani is a seasoned clinical research professional with a proven track record in managing complex, multi-regional clinical trials across North America, Europe, Asia-Pacific, and Africa. Based in Singapore, Hardik brings over a decade of experience in clinical operations, portfolio oversight, and project finance. He is a certified Project Management Professional (PMP) and was recognized with the Bronze award at the 2020 PharmaTimes International Clinical Researcher of the Year competition. Hardik’s expertise spans the full spectrum of clinical trial delivery—from startup through closeout—with a strong command of clinical systems including CTMS and EDC platforms. His leadership style emphasizes collaboration, operational excellence, and a deep commitment to advancing global health through precision-driven research., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hardik%20Badani.png',altText='Hardik Badani',fileId=197937156662}, lastname=Badani, hs_initial_published_at=1761062733198, hs_created_by_user_id=26433386, hs_created_at=1761062663685, hs_is_edited=false, hs_deleted_at=0, name=Hardik, job=Principal Clinical Trial Manager, slug=hardik-badani, hs_updated_by_user_id=51739740}, third={}})

Helen O.
Hardik B.

Discover

Translational Research - Lab Services

Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

Nov 10, ‘25 | 9 min read

has third author: false, (SizeLimitingPyMap: {main={hs_id=159488778872, hs_child_table_id=0, hs_updated_at=1744653337128, hs_published_at=1764696947929, description=Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Darren%20Davis.webp',altText='Darren Davis',fileId=165891429693}, linkedin=https://www.linkedin.com/in/drdarrendavis, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Davis, PhD, hs_initial_published_at=1764696935600, hs_created_at=1709645745103, hs_is_edited=false, hs_deleted_at=0, name=Darren, job=Senior Vice President, Translational Sciences, slug=darren-davis, email=, hs_updated_by_user_id=51739740}, second={hs_id=167888548278, hs_child_table_id=0, hs_updated_at=1722451546286, hs_published_at=1764696947929, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716194887110, hs_created_by_user_id=2737751, hs_created_at=1716194842710, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job=Chief Scientific Officer, slug=deborah-phippard-translational-sciences, email=, hs_updated_by_user_id=51739740}, third={hs_id=159488778886, hs_child_table_id=0, hs_updated_at=1763657611624, hs_published_at=1764696947929, description=Robert Snyder, PhD, is a seasoned expert with a 20-year track record in genomics, specializing in in vitro diagnostic assay development and bioinformatics. Committed to advancing medical science, he is proficient in regulatory V&V study designs and understands the nuances of orthogonal methods. A collaborative partner in biomedical development, Dr. Snyder champions the critical transition of biospecimens from benchtop to bedside., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Snyder.webp',altText='Robert Snyder',fileId=165892444501}, linkedin=https://www.linkedin.com/in/robert-snyder-ph-d-9b67b035, hs_name=, hs_path=, lastname=Snyder, PhD, hs_initial_published_at=1764696935600, hs_created_at=1709645745117, hs_is_edited=false, hs_deleted_at=0, name=Robert, job=, slug=robert-snyder, email=, hs_updated_by_user_id=51739740}})

Darren D.

Deborah P.

Robert S.

Discover

Pioneer new therapies with Precision expertise

With Precision, your pioneering treatments in Oncology, Rare Diseases, and beyond are propelled from concept to reality, supported by teams with deep domain expertise and innovative approaches.

Oncology Explore